Kadimastem Ltd (KMSTF)
Kadimastem Ltd operates in the Biotechnology industry of the Healthcare sector, headquartered in Ness Ziona, IL. The stock last traded at $3.21, down 3.02% on the session, giving a market capitalisation of $9.5M. On trailing twelve-month figures it carries a trailing P/E of -1.51, a net margin of 0.0%. Its beta of 0.57 implies it has historically moved less than the broad market.
Kadimastem Ltd, an Israeli biopharmaceutical company, focuses on pioneering regenerative medicine therapies that utilize cells originating from human embryonic stem cells, primarily targeting neurodegenerative disorders. Its developmental pipeline features AstroRx, a clinical-grade human astrocyte therapy presently undergoing Phase 1/2a clinical trials for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions. Additionally, the company is developing IsletRx, a clinical-grade pancreatic islet cell therapy designed to treat diabetes. Founded in 2008, Kadimastem maintains its headquarters in Ness Ziona, Israel.
Kadimastem Ltd is most often compared with the following Healthcare names: